scholarly journals Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles

Oncotarget ◽  
2017 ◽  
Vol 8 (36) ◽  
pp. 60453-60468 ◽  
Author(s):  
Liang Zou ◽  
Di Wang ◽  
Yichen Hu ◽  
Chaomei Fu ◽  
Wei Li ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Drug Resistance ◽  
Combination Therapy ◽  
Cancer Cells ◽  
Ovarian Cancer Cells ◽  
Resistance Reversal

scholarly journals Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy‐mediated drug resistance in ovarian cancer cells, xenografts, and patient‐derived xenograft models

Cancer ◽  
2019 ◽  
Vol 126 (4) ◽  
pp. 894-907 ◽  
Author(s):  
Janice M. Santiago‐O’Farrill ◽  
S. John Weroha ◽  
Xiaonan Hou ◽  
Ann L. Oberg ◽  
Ethan P. Heinzen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Drug Resistance ◽  
Cancer Cells ◽  
Adenosine Diphosphate ◽  
Ovarian Cancer Cells ◽  
Patient Derived Xenograft ◽  
Polymerase Inhibitors ◽  
Xenograft Models

scholarly journals Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development

2018 ◽  
Vol 20 (1) ◽  
pp. 54 ◽  
Author(s):  
Karolina Sterzyńska ◽  
Andrzej Klejewski ◽  
Karolina Wojtowicz ◽  
Monika Świerczewska ◽  
Marta Nowacka ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Extracellular Matrix ◽  
Drug Resistance ◽  
Cancer Cells ◽  
Cell Lines ◽  
Cancer Cell ◽  
Lysyl Oxidase ◽  
Resistant Cell ◽  
Pcr Analysis ◽  
Ovarian Cancer Cells

A major contributor leading to treatment failure of ovarian cancer patients is the drug resistance of cancer cell. CSCs- (cancer stem cells) and ECM (extracellular matrix)-related models of drug resistance are described as independently occurring in cancer cells. Lysyl oxidase (LOX) is another extracellular protein involved in collagen cross-linking and remodeling of extracellular matrix and has been correlated with tumor progression. The expression of LOX, COL1A2, COL3A1, and ALDH1A1 was performed in sensitive (A2780, W1) and resistant to paclitaxel (PAC) (A2780PR1 and W1PR2) and topotecan (TOP) (W1TR) cell lines at the mRNA (real-time PCR analysis) and protein level (Western blot and immunofluorescence analysis). The ALDH1A1 activity was measured with the ALDEFLUOR test and flow cytometry analysis. The protein expression in ovarian cancer tissues was determined by immunohistochemistry. We observed an increased expression of LOX and collagens in PAC and TOP resistant cell lines. Subpopulations of ALDH1A1 positive and negative cells were also noted for examined cell lines. Additionally, the coexpression of LOX with ALDH1A1 and COL1A2 with ALDH1A1 was observed. The expression of LOX, collagens, and ALDH1A1 was also detected in ovarian cancer lesions. In our study LOX, ALDH1A1 and collagens were found to be coordinately expressed by cells resistant to PAC (LOX, ALDH1A1, and COL1A2) or to TOP (LOX and ALDH1A1). This represents the study where molecules related with CSCs (ALDH1A1) and ECM (LOX, collagens) models of drug resistance are described as occurring simultaneously in ovarian cancer cells treated with PAC and TOP.

Glucosamine reverses drug resistance in MRP2 overexpressing ovarian cancer cells

2020 ◽  
Vol 868 ◽  
pp. 172883 ◽  
Author(s):  
Fatemeh Valinezhad Sani ◽  
Abbasali Palizban ◽  
Fatemeh Mosaffa ◽  
Khadijeh Jamialahmadi
Keyword(s):  
Ovarian Cancer ◽  
Drug Resistance ◽  
Cancer Cells ◽  
Ovarian Cancer Cells

MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells

2007 ◽  
Vol 27 (6) ◽  
pp. 721-724 ◽  
Author(s):  
Lirong Ren ◽  
Lan Xiao ◽  
Jianli Hu ◽  
Zhimin Li ◽  
Zehua Wang
Keyword(s):  
Ovarian Cancer ◽  
Drug Resistance ◽  
Cancer Cells ◽  
Ovarian Cancer Cells
Sign in / Sign up

Export Citation Format

Share Document